Australia's Healius rises on sale of unit Agilex Biolabs to Novotech Health

Healius

25/09/2026 01:15

** Shares of Australia's Healius HLS.AX rise as much as 18.1% to A$0.425, their biggest intraday gain since August 20
** Stock hits highest level since September 18 
** Healthcare firm agrees to sell its unit Agilex Biolabs to subsidiary of Novotech Health for enterprise value of A$160 million ($112.06 million)
** Expects cash proceeds of A$155 million after costs
** Says Agilex Biolabs' disposal at a sufficiently attractive price would unlock value for shareholders and support management focus on ongoing growth of Healius' core Pathology business.
** Stock down 55.8% YTD 
     
     
($1 = 1.4278 Australian dollars)

(Reporting by Sneha Kumar in Bengaluru)
((Sneha.Kumar@thomsonreuters.com;))